Phase I/II trial of heat shock protein peptide complex-96 (HSPPC-96) vaccine for patients with recurrent high grade glioma.

Trial Profile

Phase I/II trial of heat shock protein peptide complex-96 (HSPPC-96) vaccine for patients with recurrent high grade glioma.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 07 Dec 2016

At a glance

  • Drugs Vitespen (Primary) ; Temozolomide
  • Indications Glioblastoma; Glioma; Oligodendroglioma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 17 Sep 2013 Status changed from active, no longer recruiting to completed based on information reported in an Agenus media release.
    • 17 Sep 2013 Final results are expected to be published in a scientific journal in 2014 according to an Agenus media release.
    • 01 May 2013 Final trial results of this study are expected to be published in a scientific journal in 2013, according to an Agenus media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top